Pembrolizumab
Constitutional Mismatch Repair Deficiency Syndrome
ImmunoVaccine Technologies, Inc. (IMV Inc.)monoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Constitutional Mismatch Repair Deficiency Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 2 | CCC |
Dpx-Survivac ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 2 | CCC |
Ipilimumab Incyte Corporation | Phase 1 | CC |
Nivolumab National Cancer Institute (NCI) | Phase 1 | CC |
Ipilimumab Incyte Corporation | Phase 1 | CC |
Incb099280 Incyte Corporation | Phase 1 | C |
Incb099280 Incyte Corporation | Phase 1 | NR |
Same molecule, other indications
Pembrolizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →